PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27322737-4	2016	Here, our study showed that nafamostat mesilate abrogated the constitutive NF-kappaB activation in CRC cells, which is mediated through inhibition of phosphorylation of IkappaBalpha and nuclear translocation of p65.	nafamostat	28-38	nuclear factor kappa B subunit 1	Homo sapiens	75-84	
27322737-7	2016	Furthermore, nafamostat mesilate could reverse oxaliplatin induced NF-kappaB and Erk activation in CRC cells, and enhance the sensitivity of CRC cells to oxaliplatin.	nafamostat	13-32	nuclear factor kappa B subunit 1	Homo sapiens	67-76	
27322737-9	2016	Overall, our data suggest that nafamostat mesilate, a relatively non-toxic drug that targets NF-kappaB and Erk, may, in combination with oxaliplatin, represent a novel therapeutic strategy for CRC treatment.	nafamostat	31-50	nuclear factor kappa B subunit 1	Homo sapiens	93-102